Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients.

Breast cancer research and treatment

Volumn 140, Issue 3, 2013, Pages 463-473

  Engstrom M J ^a   Opdahl, S ^b   Hagen, A I ^b   Romundstad, P R ^b   Akslen, L A ^b   Haugen, O A ^b   Vatten, L J ^b   Bofin, A M ^b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; BREAST TUMOR; COHORT ANALYSIS; EPIDEMIOLOGY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; NORWAY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TISSUE MICROARRAY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; NORWAY; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS;

EID: 84898704104     PISSN: None     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2647-2     Document Type: Article

References (44)

1. 1. JM Bartlett J Starczynski N Atkey E Kay A O’Grady M Gandy M Ibrahim B Jasani IO Ellis SE Pinder RA Walker 2011 HER2 testing in the UK: recommendations for breast and gastric in situ hybridisation methods J Clin Pathol 64 649 653 10.1136/jcp.2011.089847 21690244 10.1136/jcp.2011.089847 1:STN:280:DC%2BC3MnpslCitg%3D%3D Bartlett JM, Starczynski J, Atkey N, Kay E, O’Grady A, Gandy M, Ibrahim M, Jasani B, Ellis IO, Pinder SE, Walker RA (2011) HER2 testing in the UK: recommendations for breast and gastric in situ hybridisation methods. J Clin Pathol 64:649–653. doi: 10.1136/jcp.2011.089847
2. 2. R Bhargava S Beriwal K McManus DJ Dabbs 2008 CK5 is more sensitive than CK5/6 in identifying the “basal-like” phenotype of breast carcinoma Am J Clin Pathol 130 724 730 10.1309/ajcp3kff1ltywqiy 18854264 10.1309/AJCP3KFF1LTYWQIY 1:CAS:528:DC%2BD1cXhsVSjtrbF Bhargava R, Beriwal S, McManus K, Dabbs DJ (2008) CK5 is more sensitive than CK5/6 in identifying the “basal-like” phenotype of breast carcinoma. Am J Clin Pathol 130:724–730. doi: 10.1309/ajcp3kff1ltywqiy
3. 3. HJ Bloom WW Richardson 1957 Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years Br J Cancer 11 359 377 13499785 10.1038/bjc.1957.43 1:STN:280:DyaG1c%2Fkt1Gmtg%3D%3D Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359–377
4. 4. FM Blows KE Driver MK Schmidt A Broeks FE Leeuwen van J Wesseling MC Cheang K Gelmon TO Nielsen C Blomqvist P Heikkila T Heikkinen H Nevanlinna LA Akslen LR Begin WD Foulkes FJ Couch X Wang V Cafourek JE Olson L Baglietto GG Giles G Severi CA McLean MC Southey E Rakha AR Green IO Ellis ME Sherman J Lissowska WF Anderson A Cox SS Cross MW Reed E Provenzano SJ Dawson AM Dunning M Humphreys DF Easton M Garcia-Closas C Caldas PD Pharoah D Huntsman 2010 Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies PLoS Med 7 e1000279 10.1371/journal.pmed.1000279 20520800 10.1371/journal.pmed.1000279 Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkila P, Heikkinen T, Nevanlinna H, Akslen LA, Begin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, Garcia-Closas M, Caldas C, Pharoah PD, Huntsman D (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7:e1000279. doi: 10.1371/journal.pmed.1000279
5. 5. A Caldarella D Puliti E Crocetti S Bianchi V Vezzosi P Apicella M Biancalani A Giannini C Urso F Zolfanelli E Paci 2012 Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening J Cancer Res Clin Oncol 10.1007/s00432-012-1304-1 Caldarella A, Puliti D, Crocetti E, Bianchi S, Vezzosi V, Apicella P, Biancalani M, Giannini A, Urso C, Zolfanelli F, Paci E (2012) Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening. J Cancer Res Clin Oncol. doi: 10.1007/s00432-012-1304-1
6. 6. MC Cheang D Voduc C Bajdik S Leung S McKinney SK Chia CM Perou TO Nielsen 2008 Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype Clin Cancer Res 14 1368 1376 10.1158/1078-0432.ccr-07-1658 18316557 10.1158/1078-0432.CCR-07-1658 1:CAS:528:DC%2BD1cXislSrs7o%3D Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376. doi: 10.1158/1078-0432.ccr-07-1658
7. 7. N Chowdhury 2011 Histopathological and genomic grading provide complementary prognostic information in breast cancer: a study on publicly available datasets Pathol Res Int 2011 890938 10.4061/2011/890938 Chowdhury N (2011) Histopathological and genomic grading provide complementary prognostic information in breast cancer: a study on publicly available datasets. Pathol Res Int 2011:890938. doi: 10.4061/2011/890938
8. 8. S Dawood R Hu MD Homes LC Collins SJ Schnitt J Connolly GA Colditz RM Tamimi 2011 Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study Breast Cancer Res Treat 126 185 192 10.1007/s10549-010-1113-7 20711652 10.1007/s10549-010-1113-7 Dawood S, Hu R, Homes MD, Collins LC, Schnitt SJ, Connolly J, Colditz GA, Tamimi RM (2011) Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat 126:185–192. doi: 10.1007/s10549-010-1113-7
9. 9. SJ Dawson SW Duffy FM Blows KE Driver E Provenzano J LeQuesne DC Greenberg P Pharoah C Caldas GC Wishart 2009 Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival Br J Cancer 101 1338 1344 10.1038/sj.bjc.6605317 19773756 10.1038/sj.bjc.6605317 1:CAS:528:DC%2BD1MXht1GntbnL Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J, Greenberg DC, Pharoah P, Caldas C, Wishart GC (2009) Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer 101:1338–1344. doi: 10.1038/sj.bjc.6605317
10. 10. B Deyarmin JL Kane AL Valente R Laar van C Gallagher CD Shriver RE Ellsworth 2013 Effect of ASCO/CAP guidelines for determining ER status on molecular subtype Ann Surg Oncol 20 87 93 10.1245/s10434-012-2588-8 22875649 10.1245/s10434-012-2588-8 Deyarmin B, Kane JL, Valente AL, van Laar R, Gallagher C, Shriver CD, Ellsworth RE (2013) Effect of ASCO/CAP guidelines for determining ER status on molecular subtype. Ann Surg Oncol 20:87–93. doi: 10.1245/s10434-012-2588-8
11. 11. S Palma Di N Collins M Bilous A Sapino M Mottolese N Kapranos F Schmitt J Isola 2008 A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer J Clin Pathol 61 757 760 10.1136/jcp.2007.053850 18326010 10.1136/jcp.2007.053850 Di Palma S, Collins N, Bilous M, Sapino A, Mottolese M, Kapranos N, Schmitt F, Isola J (2008) A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer. J Clin Pathol 61:757–760. doi: 10.1136/jcp.2007.053850
12. 12. CW Elston IO Ellis 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 403 410 1757079 10.1111/j.1365-2559.1991.tb00229.x 1:STN:280:DyaK38%2FpvVSltw%3D%3D Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410
13. 13. J Ferlay HR Shin F Bray D Forman C Mathers DM Parkin 2010 Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2893 2917 10.1002/ijc.25516 21351269 10.1002/ijc.25516 1:CAS:528:DC%2BC3cXhtlWhs7fO Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917. doi: 10.1002/ijc.25516
14. 14. WD Foulkes IM Stefansson PO Chappuis LR Begin JR Goffin N Wong M Trudel LA Akslen 2003 Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer J Natl Cancer Inst 95 1482 1485 14519755 10.1093/jnci/djg050 1:CAS:528:DC%2BD3sXnvVCjtrk%3D Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482–1485
15. 15. M Gnant N Harbeck C Thomssen 2011 St. Gallen 2011: Summary of the Consensus Discussion Breast Care (Basel) 6 136 141 10.1159/000328054 10.1159/000328054 Gnant M, Harbeck N, Thomssen C (2011) St. Gallen 2011: Summary of the Consensus Discussion. Breast Care (Basel) 6:136–141. doi: 10.1159/000328054
16. 16. A Goldhirsch JN Ingle RD Gelber AS Coates B Thurlimann HJ Senn 2009 Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 1319 1329 10.1093/annonc/mdp322 19535820 10.1093/annonc/mdp322 1:STN:280:DC%2BD1Mrjtlyhug%3D%3D Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319–1329. doi: 10.1093/annonc/mdp322
17. 17. A Goldhirsch WC Wood AS Coates RD Gelber B Thurlimann HJ Senn 2011 Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Ann Oncol 22 1736 1747 10.1093/annonc/mdr304 21709140 10.1093/annonc/mdr304 1:STN:280:DC%2BC3Mjhs1ygug%3D%3D Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736–1747. doi: 10.1093/annonc/mdr304
18. 18. S Guiu S Michiels F Andre J Cortes C Denkert A Leo Di BT Hennessy T Sorlie C Sotiriou N Turner M Vijver Van de G Viale S Loi JS Reis-Filho 2012 Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 working group statement Ann Oncol 23 2997 3006 10.1093/annonc/mds586 23166150 10.1093/annonc/mds586 1:STN:280:DC%2BC3s7ksl2guw%3D%3D Guiu S, Michiels S, Andre F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, Van de Vijver M, Viale G, Loi S, Reis-Filho JS (2012) Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 working group statement. Ann Oncol 23:2997–3006. doi: 10.1093/annonc/mds586
19. 19. ME Hammond DF Hayes M Dowsett DC Allred KL Hagerty S Badve PL Fitzgibbons G Francis NS Goldstein M Hayes DG Hicks S Lester R Love PB Mangu L McShane K Miller CK Osborne S Paik J Perlmutter A Rhodes H Sasano JN Schwartz FC Sweep S Taube EE Torlakovic P Valenstein G Viale D Visscher T Wheeler RB Williams JL Wittliff AC Wolff 2010 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer Arch Pathol Lab Med 134 907 922 10.1043/1543-2165-134.6.907 20524868 Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 134:907–922. doi: 10.1043/1543-2165-134.6.907
20. 20. N Hayashi N Niikura H Yamauchi S Nakamura NT Ueno 2013 Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer Breast Cancer Res Treat 137 523 531 10.1007/s10549-012-2336-6 23184079 10.1007/s10549-012-2336-6 1:CAS:528:DC%2BC3sXmtVCjuw%3D%3D Hayashi N, Niikura N, Yamauchi H, Nakamura S, Ueno NT (2013) Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer. Breast Cancer Res Treat 137:523–531. doi: 10.1007/s10549-012-2336-6
21. 21. S Hofvind CI Lee JG Elmore 2012 Stage-specific breast cancer incidence rates among participants and non-participants of a population-based mammographic screening program Breast Cancer Res Treat 135 291 299 10.1007/s10549-012-2162-x 22833199 10.1007/s10549-012-2162-x Hofvind S, Lee CI, Elmore JG (2012) Stage-specific breast cancer incidence rates among participants and non-participants of a population-based mammographic screening program. Breast Cancer Res Treat 135:291–299. doi: 10.1007/s10549-012-2162-x
22. 22. G Kvåle I Heuch G Eide 1987 A prospective study of reproductive factors and breast cancer Am J Epidemiol 126 831 841 3661531 Kvåle G, Heuch I, Eide G (1987) A prospective study of reproductive factors and breast cancer. Am J Epidemiol 126:831–841
23. 23. Lakhani SR, Ellis I, Schnitt SJ, Tan PH, Van de Vijver M, World Health Organization (eds) (2012) WHO Classification of Tumours of the Breast. International Agency for Research on Cancer (IARC), Lyon
24. 24. AS Leong Z Zhuang 2011 The changing role of pathology in breast cancer diagnosis and treatment Pathobiology 78 99 114 10.1159/000292644 21677473 10.1159/000292644 1:CAS:528:DC%2BC3MXnsFWktbw%3D Leong AS, Zhuang Z (2011) The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology 78:99–114. doi: 10.1159/000292644
25. 25. LM McShane DG Altman W Sauerbrei SE Taube M Gion GM Clark 2006 REporting recommendations for tumor MARKer prognostic studies (REMARK) Breast Cancer Res Treat 100 229 235 10.1007/s10549-006-9242-8 16932852 10.1007/s10549-006-9242-8 McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235. doi: 10.1007/s10549-006-9242-8
26. 26. H Nalwoga JB Arnes H Wabinga LA Akslen 2007 Frequency of the basal-like phenotype in African breast cancer APMIS 115 1391 1399 10.1111/j.1600-0463.2007.00862.x 18184410 10.1111/j.1600-0463.2007.00862.x Nalwoga H, Arnes JB, Wabinga H, Akslen LA (2007) Frequency of the basal-like phenotype in African breast cancer. APMIS 115:1391–1399. doi: 10.1111/j.1600-0463.2007.00862.x
27. 27. N Norton EA Perez 2013 How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer? Breast Cancer Res 15 101 10.1186/bcr3335 23316883 10.1186/bcr3335 Norton N, Perez EA (2013) How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer? Breast Cancer Res 15:101. doi: 10.1186/bcr3335
28. 28. Y Ogawa T Moriya Y Kato M Oguma K Ikeda T Takashima B Nakata T Ishikawa K Hirakawa 2004 Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy Breast Cancer 11 267 275 15550845 10.1007/BF02984548 Ogawa Y, Moriya T, Kato Y, Oguma M, Ikeda K, Takashima T, Nakata B, Ishikawa T, Hirakawa K (2004) Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer 11:267–275
29. 29. S Opdahl MD Alsaker I Janszky PR Romundstad LJ Vatten 2011 Joint effects of nulliparity and other breast cancer risk factors Br J Cancer 105 731 736 10.1038/bjc.2011.286 21811252 10.1038/bjc.2011.286 1:STN:280:DC%2BC3Mjot1Oqtg%3D%3D Opdahl S, Alsaker MD, Janszky I, Romundstad PR, Vatten LJ (2011) Joint effects of nulliparity and other breast cancer risk factors. Br J Cancer 105:731–736. doi: 10.1038/bjc.2011.286
30. 30. CM Perou T Sorlie MB Eisen M Rijn van de SS Jeffrey CA Rees JR Pollack DT Ross H Johnsen LA Akslen O Fluge A Pergamenschikov C Williams SX Zhu PE Lonning AL Borresen-Dale PO Brown D Botstein 2000 Molecular portraits of human breast tumours Nature 406 747 752 10.1038/35021093 10963602 10.1038/35021093 1:CAS:528:DC%2BD3cXmt1CnsLw%3D Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747–752. doi: 10.1038/35021093
31. 31. CA Purdie LB Jordan JB McCullough SL Edwards J Cunningham M Walsh A Grant N Pratt AM Thompson 2010 HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma Histopathology 56 702 707 10.1111/j.1365-2559.2010.03533.x 20546335 10.1111/j.1365-2559.2010.03533.x Purdie CA, Jordan LB, McCullough JB, Edwards SL, Cunningham J, Walsh M, Grant A, Pratt N, Thompson AM (2010) HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma. Histopathology 56:702–707. doi: 10.1111/j.1365-2559.2010.03533.x
32. 32. EA Rakha JS Reis-Filho F Baehner DJ Dabbs T Decker V Eusebi SB Fox S Ichihara J Jacquemier SR Lakhani J Palacios AL Richardson SJ Schnitt FC Schmitt PH Tan GM Tse S Badve IO Ellis 2010 Breast cancer prognostic classification in the molecular era: the role of histological grade Breast Cancer Res 12 207 10.1186/bcr2607 20804570 Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Richardson AL, Schnitt SJ, Schmitt FC, Tan PH, Tse GM, Badve S, Ellis IO (2010) Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 12:207. doi: 10.1186/bcr2607
33. 33. P Robbins S Pinder N Klerk de H Dawkins J Harvey G Sterrett I Ellis C Elston 1995 Histological grading of breast carcinomas: a study of interobserver agreement Hum Pathol 26 873 879 7635449 10.1016/0046-8177(95)90010-1 1:STN:280:DyaK2Mzmt1ahtA%3D%3D Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, Ellis I, Elston C (1995) Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 26:873–879
34. 34. G Sauter J Lee JM Bartlett DJ Slamon MF Press 2009 Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations J Clin Oncol 27 1323 1333 10.1200/jco.2007.14.8197 19204209 10.1200/JCO.2007.14.8197 1:CAS:528:DC%2BD1MXktFKhsbs%3D Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27:1323–1333. doi: 10.1200/jco.2007.14.8197
35. 35. I Soerjomataram J Lortet-Tieulent DM Parkin J Ferlay C Mathers D Forman F Bray 2012 Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions Lancet 380 1840 1850 10.1016/s0140-6736(12)60919-2 23079588 10.1016/S0140-6736(12)60919-2 Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, Bray F (2012) Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 380:1840–1850. doi: 10.1016/s0140-6736(12)60919-2
36. 36. I Soerjomataram MW Louwman JG Ribot JA Roukema JW Coebergh 2008 An overview of prognostic factors for long-term survivors of breast cancer Breast Cancer Res Treat 107 309 330 10.1007/s10549-007-9556-1 17377838 10.1007/s10549-007-9556-1 1:CAS:528:DC%2BD1cXht1Sgtrw%3D Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW (2008) An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 107:309–330. doi: 10.1007/s10549-007-9556-1
37. 37. C Sotiriou P Wirapati S Loi A Harris S Fox J Smeds H Nordgren P Farmer V Praz B Haibe-Kains C Desmedt D Larsimont F Cardoso H Peterse D Nuyten M Buyse MJ Vijver Van de J Bergh M Piccart M Delorenzi 2006 Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis J Natl Cancer Inst 98 262 272 10.1093/jnci/djj052 16478745 10.1093/jnci/djj052 1:CAS:528:DC%2BD28Xhs1Skt74%3D Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262–272. doi: 10.1093/jnci/djj052
38. 38. BM Syed AR Green EC Paish D Soria J Garibaldi L Morgan DA Morgan IO Ellis KL Cheung 2013 Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts Br J Cancer 108 1042 1051 10.1038/bjc.2012.601 23462719 10.1038/bjc.2012.601 1:CAS:528:DC%2BC3sXksVKku7g%3D Syed BM, Green AR, Paish EC, Soria D, Garibaldi J, Morgan L, Morgan DA, Ellis IO, Cheung KL (2013) Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts. Br J Cancer 108:1042–1051. doi: 10.1038/bjc.2012.601
39. 39. B Szekely T Iwamoto AM Szasz Y Qi J Matsuoka WF Symmans AM Tokes J Kulka C Swanton L Pusztai 2013 A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2. ER-positive breast cancers into low-and high-risk prognostic categories Breast Cancer Res Treat 10.1007/s10549-013-2475-4 23504136 Szekely B, Iwamoto T, Szasz AM, Qi Y, Matsuoka J, Symmans WF, Tokes AM, Kulka J, Swanton C, Pusztai L (2013) A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2. ER-positive breast cancers into low-and high-risk prognostic categories. Breast Cancer Res Treat. doi: 10.1007/s10549-013-2475-4
40. 40. M Tischkowitz JS Brunet LR Begin DG Huntsman MC Cheang LA Akslen TO Nielsen WD Foulkes 2007 Use of immunohistochemical markers can refine prognosis in triple negative breast cancer BMC Cancer 7 134 10.1186/1471-2407-7-134 17650314 10.1186/1471-2407-7-134 Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7:134. doi: 10.1186/1471-2407-7-134
41. 41. I Vaz-Luis RA Ottesen ME Hughes PK Marcom B Moy HS Rugo RL Theriault J Wilson JC Niland JC Weeks NU Lin 2012 Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study Breast Cancer Res 14 R129 10.1186/bcr3324 23025714 10.1186/bcr3324 1:CAS:528:DC%2BC3sXjsFSjtL8%3D Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, Theriault RL, Wilson J, Niland JC, Weeks JC, Lin NU (2012) Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res 14:R129. doi: 10.1186/bcr3324
42. 42. I Vaz-Luis EP Winer NU Lin 2013 Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Ann Oncol 24 283 291 10.1093/annonc/mds286 23022997 10.1093/annonc/mds286 1:STN:280:DC%2BC3s%2FhtF2quw%3D%3D Vaz-Luis I, Winer EP, Lin NU (2013) Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Ann Oncol 24:283–291. doi: 10.1093/annonc/mds286
43. 43. RA Walker JM Bartlett M Dowsett IO Ellis AM Hanby B Jasani K Miller SE Pinder 2008 HER2 testing in the UK: further update to recommendations J Clin Pathol 61 818 824 10.1136/jcp.2007.054866 18381380 10.1136/jcp.2007.054866 1:STN:280:DC%2BD1cvhsFegsQ%3D%3D Walker RA, Bartlett JM, Dowsett M, Ellis IO, Hanby AM, Jasani B, Miller K, Pinder SE (2008) HER2 testing in the UK: further update to recommendations. J Clin Pathol 61:818–824. doi: 10.1136/jcp.2007.054866
44. 44. J Warwick L Tabar B Vitak SW Duffy 2004 Time-dependent effects on survival in breast carcinoma: results of 20 years of follow-up from the Swedish two-county study Cancer 100 1331 1336 10.1002/cncr.20140 15042664 10.1002/cncr.20140 Warwick J, Tabar L, Vitak B, Duffy SW (2004) Time-dependent effects on survival in breast carcinoma: results of 20 years of follow-up from the Swedish two-county study. Cancer 100:1331–1336. doi: 10.1002/cncr.20140